AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01713946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug (1 to 3 only)
Description: no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
Study NCT01713946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antiepileptic drug (1 to 3 only)
Description: no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
Study NCT01713946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open label RAD001 (only used for post-extension phase)
Description: everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
Study NCT01713946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: open label RAD001 (only used for post-extension phase)
Description: everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
Study NCT02738372 — intervention group
Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
Study NCT03183518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial micellar cleanser
Description: Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
Study NCT03183518 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline Solution: Sodium Chloride (NaCl; 0.9%)
Description: Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
Study NCT02457845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G207
Description: Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
Study NCT03995446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser
Description: low level laser emission on specific acupuncture points
Study NCT03995446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser
Study NCT03093298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteroscopy with biopsy sampling and mixed meal test
Description: Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
Study NCT00666068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corticotropin releasing hormone (CRH)
Description: 50 µg injected at 2200, 2300, 0000, and 0100
Study NCT00666068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: injected at 2200, 2300, 0000, and 0100
Study NCT00666068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injected at 2200, 2300, 0000, and 0100
Study NCT00687011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron and Dexamethasone
Description: 0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
Study NCT03268577 — intervention group
Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Complete ASA24
Study NCT03268577 — intervention group
Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Complete ACT24 reporting
Study NCT03268577 — intervention group
Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear accelerometer and inclinometer physical activity monitors
Study NCT03268577 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00644475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidapril
Description: tablets; 5, 10, 15, 20 mg; od; 12 weeks
Study NCT00644475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: tablets; 8, 16, 24, and 32 mg; od; 12 weeks
Study NCT00592241 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Adi Insulin Pump Usability
Description: no intervention
Study NCT04781439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV-to-PO conversion of antibiotics
Description: IV-to-PO switching of antibiotics treatment
Study NCT01215552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-0712
Description: A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
Study NCT00393484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
Study NCT00393484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Placebo
Description: Capsules, Oral, 0 mg, once daily (0-96 weeks)
Study NCT00393484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)
Study NCT00393484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir Placebo
Description: Tablets, Oral, 0 mg, once daily (0-96 weeks)
Study NCT01764464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gralise®
Description: 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
Study NCT01764464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
Study NCT02462499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inspra (eplerenone)
Study NCT00001277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate
Description: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
Study NCT00001277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA
Description: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
Study NCT01069471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella vaccine
Description: Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
Study NCT02400099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein low calorie diet
Study NCT02400099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control low calorie diet
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anthropometrical measurements
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometrical measurements
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body composition
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body composition
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8-h metabolic profile
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8-h metabolic profile
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liver biopsy
Study NCT02400099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liver biopsy
Study NCT00715494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive, physical, and functional rehabilitation
Description: A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
Study NCT01563380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
Study NCT01094613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Release 6 mercaptopurine
Description: Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.
Study NCT01094613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine
Description: Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
Study NCT02487927 — intervention group
Intervention type: BEHAVIORAL
Intervention: weaning
Description: T piece
Study NCT04565834 — intervention group
Intervention type: GENETIC
Intervention: Analysis of Single nucleotide polymorphisms in each group.
Description: The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.
Study NCT02190578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal G4
Description: All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
Study NCT01982890 — intervention group
Intervention type: OTHER
Intervention: Control
Description: No intervention as this group is simply followed prospectively.
Study NCT00716924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300 mg
Study NCT00716924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg
Study NCT04177459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoting dialogue
Description: Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
Study NCT04177459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment / treatment as usual
Description: Follow-up from primary and secondary health care, and from schools.
Study NCT04177459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment / treatment as usual
Description: Follow-up from primary and secondary health care, and from schools.
Study NCT02617069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin injection
Study NCT02617069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline injection
Study NCT02617069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder
Study NCT02617069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study NCT00614926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
Study NCT04004117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate solution sublingual
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
Study NCT04004117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl citrate solution sublingual
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
Study NCT04004117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral liquid
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
Study NCT04004117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral liquid
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
Study NCT02547766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
Study NCT01826461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-192
Study NCT01826461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT04674397 — intervention group
Intervention type: RADIATION
Intervention: Radioisotope GFR test
Study NCT02649543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
Study NCT02649543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Primary Closure
Description: A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
Study NCT00849251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or PO
Study NCT00849251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT00849251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT03757780 — intervention group
Intervention type: OTHER
Intervention: Questionaire
Description: A questionaire will be made to pregnant ladies who take caffeine during pregnancy
Study NCT01913379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral
Study NCT01913379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral
Study NCT01913379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral
Study NCT04768894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second transurehral resection of bladder tumour
Description: Remove of the bladder tumour as endoscopically
Study NCT02159937 — intervention group
Intervention type: OTHER
Intervention: Blood sampling by vena punction.
Description: In vitro tests will be performed after blood sample collection from metastatic cancer patients
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 3+5 (given daily x 4 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Cycle 3+5 (given daily for 3 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Cycle 4+6 (given daily for 3 days)
Study NCT00849251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO
Study NCT01354093 — intervention group
Intervention type: DRUG
Intervention: zeaxanthin
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
Study NCT01354093 — intervention group
Intervention type: DRUG
Intervention: zeaxanthin
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
Study NCT01409096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
Study NCT01409096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.
Study NCT00442702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mircera
Description: Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
Study NCT00442702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
Study NCT01952457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 4+6 (given daily for 2 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Cycle 4+6 (given daily for 3 days)
Study NCT02786719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
Study NCT01430819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
Description: 0.5 mL, Intramuscular
Study NCT01430819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
Description: 0.5 mL, Intramuscular
Study NCT00653159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUS)
Description: Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
Study NCT01952457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetic bypass
Study NCT02998060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Placement
Description: As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
Study NCT00653159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T380A intrauterine device (CuT380A)
Description: Teens are randomly assigned to Copper T380 after the screening visit
Study NCT02998060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)
Description: This robot will be used to guide pedicle screws into their trajectories.